Clinical Trials Logo

Peanut Hypersensitivity clinical trials

View clinical trials related to Peanut Hypersensitivity.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04761835 Withdrawn - Food Allergy Clinical Trials

STEP-IT-UP - Peanut Allergy Study for Infants

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Multicenter randomized (1:1) trial of strict avoidance versus sub-threshold dietary introduction of peanut in peanut allergic infants 4-14 months of age who react at a minimum cumulative dose of at least 430 mg of peanut protein at initial oral food challenge (OFC) for 12 months, followed by cross-over to sub-threshold dietary introduction of peanut in those randomized initially to avoidance.

NCT ID: NCT04200989 Withdrawn - Food Allergy Peanut Clinical Trials

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

NCT ID: NCT01918657 Withdrawn - Peanut Allergy Clinical Trials

Walnut Oral Immunotherapy for Tree Nut Allergy

Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn about the medical effects, safety, and how the Walnut Oral Immunotherapy (OIT) treatment affects your body (immune system). This type of immunotherapy involves giving increasing doses of walnut allergen to gradually build up a person's tolerance to walnut and at least one other tree nut. The goal of the study is to determine whether participants can tolerate (eat) walnuts and at least one other tree nut in their diet after stopping the study therapy.

NCT ID: NCT01451450 Withdrawn - Peanut Allergy Clinical Trials

Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.